Replimune Group, Inc. (REPL) · Insider trading
What Replimune Group's directors, officers and largest holders bought and sold themselves, from the Form 4 each of them files with the SEC within two business days of a trade. Open-market purchases and sales first: those are the trades somebody chose to make at the market price.
Bought, 12 months
$0
0 insiders, 0 trades
Sold, 12 months
$1.93M
7 insiders, 14% under a plan
Net, 12 months
−$1.93M
bought less sold
Latest filing
2026-08-24
filings read to 2026-11-08
Who traded, two years
| Insider | Bought | Sold | Trades | Last trade | Holds after |
|---|---|---|---|---|---|
| Patel SushilDirector, Chief Executive Officer | – | $1.14M | 5 | 2026-08-10 | 708,151 |
| Xynos KonstantinosChief Medical Officer | – | $427,866 | 5 | 2026-08-10 | 224,215 |
| Hill Emily LuisaChief Financial Officer | – | $389,905 | 5 | 2026-08-17 | 215,852 |
| Astley-Sparke PhilipDirector | – | $349,866 | 2 | 2026-05-18 | 1,412,414 |
| Sarchi ChristopherChief Commercial Officer | – | $340,469 | 6 | 2026-06-01 | 180,962 |
| Schwendenman AndrewChief Accounting Officer | – | $165,549 | 3 | 2026-08-10 | 99,425 |
| Dhingra KapilDirector | – | $32,958 | 1 | 2025-12-09 | 0 |
Open-market purchases and sales
Newest first. “Plan” marks a trade made under a 10b5-1 plan set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Holds after | Filing |
|---|---|---|---|---|---|---|---|
| 2026-08-17 | Hill Emily LuisaChief Financial Officer | Sale | 9,256 | 14.28 | $132,176 | 215,852 | Form 4 |
| 2026-08-10 | Schwendenman AndrewChief Accounting Officer | Sale | 7,632 | 12.97 | $98,987 | 99,425 | Form 4 |
| 2026-08-10 | Xynos KonstantinosChief Medical Officer | Sale | 11,447 | 12.97 | $148,468 | 224,215 | Form 4 |
| 2026-08-10 | Hill Emily LuisaChief Financial Officer | Sale | 11,448 | 12.97 | $148,481 | 225,108 | Form 4 |
| 2026-08-10 | Patel SushilDirector, Chief Executive Officer | Sale | 39,341 | 12.97 | $510,253 | 708,151 | Form 4 |
| 2026-06-01 | Sarchi ChristopherChief Commercial Officer | Saleplan | 12,000 | 9.24 | $110,880 | 180,962 | Form 4 |
| 2026-05-18 | Hill Emily LuisaChief Financial Officer | Sale | 7,812 | 5.08 | $39,685 | 236,556 | Form 4 |
| 2026-05-18 | Patel SushilDirector, Chief Executive Officer | Sale | 37,324 | 5.08 | $189,606 | 747,492 | Form 4 |
| 2026-05-18 | Astley-Sparke PhilipDirector | Sale | 17,657 | 5.08 | $89,698 | 1,412,414 | Form 4 |
| 2026-05-18 | Sarchi ChristopherChief Commercial Officer | Sale | 8,626 | 5.08 | $43,820 | 192,962 | Form 4 |
| 2026-05-18 | Schwendenman AndrewChief Accounting Officer | Sale | 7,894 | 5.08 | $40,102 | 107,057 | Form 4 |
| 2026-05-18 | Xynos KonstantinosChief Medical Officer | Sale | 14,023 | 5.08 | $71,237 | 235,662 | Form 4 |
| 2026-04-02 | Sarchi ChristopherChief Commercial Officer | Saleplan | 6,500 | 8.01 | $52,065 | 151,588 | Form 4 |
| 2025-12-09 | Dhingra KapilDirector | Sale | 3,169 | 10.40 | $32,958 | 0 | Form 4 |
| 2025-12-02 | Patel SushilDirector, Chief Executive Officer | Saleplan | 10,000 | 11.13 | $111,300 | 333,576 | Form 4 |
| 2025-11-17 | Xynos KonstantinosChief Medical Officer | Sale | 7,248 | 9.10 | $65,957 | 139,685 | Form 4 |
| 2025-11-17 | Sarchi ChristopherChief Commercial Officer | Sale | 5,208 | 9.10 | $47,393 | 123,088 | Form 4 |
| 2025-08-15 | Hill Emily LuisaChief Financial Officer | Sale | 9,154 | 5.37 | $49,157 | 134,368 | Form 4 |
| 2025-05-20 | Sarchi ChristopherChief Commercial Officer | Sale | 3,749 | 8.05 | $30,179 | 128,296 | Form 4 |
| 2025-05-20 | Hill Emily LuisaChief Financial Officer | Sale | 2,535 | 8.05 | $20,407 | 143,522 | Form 4 |
| 2025-05-20 | Patel SushilDirector, Chief Executive Officer | Sale | 25,105 | 8.06 | $202,346 | 343,576 | Form 4 |
| 2025-05-20 | Schwendenman AndrewChief Accounting Officer | Sale | 3,287 | 8.05 | $26,460 | 68,284 | Form 4 |
| 2025-05-20 | Xynos KonstantinosChief Medical Officer | Sale | 7,952 | 8.06 | $64,093 | 146,933 | Form 4 |
| 2025-05-20 | Astley-Sparke PhilipDirector | Sale | 32,279 | 8.06 | $260,169 | 1,405,071 | Form 4 |
| 2024-12-16 | Patel SushilDirector, Chief Executive Officer | Saleplan | 10,000 | 12.42 | $124,200 | 202,014 | Form 4 |
| 2024-11-18 | Sarchi ChristopherChief Commercial Officer | Sale | 5,207 | 10.78 | $56,131 | 87,045 | Form 4 |
| 2024-11-18 | Xynos KonstantinosChief Medical Officer | Sale | 7,246 | 10.78 | $78,112 | 109,885 | Form 4 |
Grants, exercises and other transactions
Pay, tax and paperwork rather than a choice to trade at the market price. Two years.
16 × grant or award2 × gift1 × option exercise
Show them
| Date | Insider | What | Shares | Price | Holds after | Filing |
|---|---|---|---|---|---|---|
| 2026-08-20 | Astley-Sparke PhilipDirector | Gift G | −50,000 | – | 1,362,414 | Form 4 |
| 2026-04-01 | Hill Emily LuisaChief Financial Officer | Grant or award A | +50,000 | – | 244,368 | Form 4 |
| 2026-04-01 | Patel SushilDirector, Chief Executive Officer | Grant or award A | +251,240 | – | 784,816 | Form 4 |
| 2026-04-01 | Schwendenman AndrewChief Accounting Officer | Grant or award A | −36,667 | – | 114,951 | Form 4 |
| 2026-04-01 | Xynos KonstantinosChief Medical Officer | Grant or award A | +50,000 | – | 249,685 | Form 4 |
| 2026-04-01 | Astley-Sparke PhilipDirector | Grant or award A | +50,000 | – | 1,430,071 | Form 4 |
| 2026-04-01 | Sarchi ChristopherChief Commercial Officer | Grant or award A | +50,000 | – | 201,588 | Form 4 |
| 2026-02-18 | Astley-Sparke PhilipDirector | Gift G | −25,000 | – | 1,380,071 | Form 4 |
| 2025-12-19 | Schwendenman AndrewChief Accounting Officer | Grant or award A | +10,000 | – | 78,284 | Form 4 |
| 2025-12-19 | Sarchi ChristopherChief Commercial Officer | Grant or award A | +35,000 | – | 158,088 | Form 4 |
| 2025-12-19 | Hill Emily LuisaChief Financial Officer | Grant or award A | +60,000 | – | 194,368 | Form 4 |
| 2025-12-19 | Xynos KonstantinosChief Medical Officer | Grant or award A | +60,000 | – | 199,685 | Form 4 |
| 2025-12-19 | Patel SushilDirector, Chief Executive Officer | Grant or award A | +200,000 | – | 533,576 | Form 4 |
| 2025-12-09 | Dhingra KapilDirector | Option exercise M | +3,169 | 1.75 | 3,169 | Form 4 |
| 2025-04-01 | Schwendenman AndrewChief Accounting Officer | Grant or award A | −33,333 | – | 71,571 | Form 4 |
| 2025-04-01 | Sarchi ChristopherChief Commercial Officer | Grant or award A | +45,000 | – | 132,045 | Form 4 |
| 2025-04-01 | Hill Emily LuisaChief Financial Officer | Grant or award A | +45,000 | – | 146,057 | Form 4 |
| 2025-04-01 | Xynos KonstantinosChief Medical Officer | Grant or award A | +45,000 | – | 154,885 | Form 4 |
| 2025-04-01 | Patel SushilDirector, Chief Executive Officer | Grant or award A | +166,667 | – | 368,681 | Form 4 |
How to read it
- Buy, sale
- Code P and S on the form: shares bought or sold in the market, at the market price. The other codes are mostly pay (a grant, an option exercised) or tax (shares the company withheld), and say little about what the insider thinks of the price.
- Plan
- A sale or purchase under a Rule 10b5-1 plan, set up in advance and running on its own schedule. Since April 2023 the form has a box for it. Much executive selling is planned and says more about diversifying than about the company.
- Holds after
- The shares the insider still held after the trade, in the form the trade was in (directly, or indirectly through a trust or a fund).
- Value
- Shares times the price the form reports, which is often an average over several fills on the day.
Read from the SEC's own quarterly data sets of Forms 3, 4 and 5, and from each day's filings since the last one. A correcting amendment replaces the lines it restates. Every row links to its filing. None of this is advice: insiders sell for many reasons, and buy for fewer.